Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.62 |
| ▸ | MAOA | P21397 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11040027 | 0.89 | MAOB (0.62) | MAOBMAOANPC1RAB9AFKBP1A | |
| SCHEMBL74037 | 0.85 | MAOB (0.68) | MAOBMAOANPC1RAB9AMAPK1 | |
| SCHEMBL11045263 | 0.85 | MAOB (0.54) | MAOBMAOANPC1RAB9AALDH1A1 | |
| SCHEMBL107322 | 0.84 | MAOB (0.83) | MAOBMAOANPC1RAB9AMAPK1 | |
| SCHEMBL8112066 | 0.84 | MAOB (0.66) | MAOBMAOANPC1RAB9AMAPK1 | |
| SCHEMBL108114 | 0.82 | MAOB (0.74) | MAOBMAOANPC1RAB9AMAPK1 | |
| SCHEMBL28900631 | 0.82 | MAOB (0.64) | MAOBMAOANPC1RAB9AMAPK1 | |
| SCHEMBL11039281 | 0.81 | MAOB (0.62) | MAOBMAOANPC1RAB9AMAPK1 | |
| SCHEMBL6782574 | 0.81 | MAOB (0.65) | MAOBMAOANPC1RAB9AMAPK1 | |
| SCHEMBL984344 | 0.81 | MAOB (0.62) | MAOBMAOANPC1RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | claimed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | claimed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | claimed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| EP-0705816-B1 | BENZENE DERIVATIVE USEFUL FOR ISCHEMIC DISEASES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2000-09-20 | — | — | EP | claimed |
| US-5998452-A | CARDIOVASCULAR DISORDERS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-12-07 | — | — | US | claimed |
| EP-0705816-A1 | BENZENE DERIVATIVE USEFUL FOR ISCHEMIC DISEASES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1996-04-10 | — | — | EP | claimed |
| EP-0131509-A2 | Photographic element containing a polymeric mordant comprising quaternized vinylimidazole and acrylonitrile recurring units | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-01-16 | — | — | EP | claimed |
| US-4450224-A | CATIONIC IMIDAZOLE-CONTAINING VINYL POLYMERS FOR SILVER HALIDE COLOR FILMS | EASTMAN KODAK COMPANY (US) | 1984-05-22 | — | — | US | claimed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | disclosed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| US-4450224-A | CATIONIC IMIDAZOLE-CONTAINING VINYL POLYMERS FOR SILVER HALIDE COLOR FILMS | EASTMAN KODAK COMPANY (US) | 1984-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | MAOB 75/4885MAOA 86/4885NPC1 1345/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | MAOB 125/4885MAOA 157/4885NPC1 1176/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | MAOB 75/4885MAOA 86/4885NPC1 1345/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | MAOB 125/4885MAOA 157/4885NPC1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.